ChemoMetec’s Strategic Acquisition Plans
ChemoMetec is actively pursuing an acquisition of Ovizio Imaging Systems SA, as disclosed in a recent company announcement. The company's move signals its intent to enhance its portfolio in the field of imaging solutions.
Diligence Process Underway
Currently, ChemoMetec is in the process of conducting due diligence regarding Ovizio Imaging Systems. This thorough evaluation is crucial and is expected to take three weeks. If all goes according to plan, the acquisition could be finalized shortly thereafter.
Expectations for Completion
As the negotiations on the final share purchase agreement continue, ChemoMetec remains optimistic about completing the acquisition in the coming weeks, provided the outcomes are favorable.
Details on Ovizio Imaging Systems
Ovizio Imaging Systems is renowned for its innovative cell counting technologies based on holographic microscopy. Their product is pivotal in bioprocessing and in the fields of cell and gene therapy, allowing for effective monitoring and management of cell cultures.
Product Features and Market Impact
The unique design of Ovizio’s cell counter enables seamless integration with customers’ bioreactors through a disposable sterilized component. This ensures that cells can be sampled for analysis without disrupting the bioprocessing workflow. Ovizio caters to a range of respected clients across the pharmaceutical and biotech sectors, underscoring its significant role in the industry. In its latest financial report, Ovizio generated EUR 1.4 million, with a substantial portion attributed to sales of consumables and service contracts.
About ChemoMetec A/S
ChemoMetec A/S is a leading developer and manufacturer of instruments that perform cell counting and various other measurements, catering primarily to the pharmaceutical, biotech, and agricultural sectors. Their dedication to innovation is reflected in their clientele, which includes some of the most prominent pharmaceutical companies worldwide.
A History of Innovation
Founded in 1997, ChemoMetec is a publicly traded company on Nasdaq OMX Copenhagen. Its commitment to pushing technological boundaries has solidified its reputation in the market. The acquisition of Ovizio Imaging Systems aligns perfectly with ChemoMetec’s vision to expand its offerings and reinforce its position in the life sciences domain.
Contact Information
For additional details, potential investors or interested parties can reach out to:
Martin Helbo Behrens, CEO
Tel.: (+45) 48 13 10 20
Kim Nicolajsen, CFO
Tel.: (+45) 48 13 10 20
Frequently Asked Questions
What is the purpose of ChemoMetec's acquisition of Ovizio?
The acquisition aims to expand ChemoMetec's capabilities in imaging and cell counting, strengthening its position in the life sciences market.
What technology does Ovizio Imaging Systems offer?
Ovizio specializes in holographic microscopy for cell counting, primarily used in bioprocessing and cell therapy applications.
How much revenue did Ovizio generate recently?
Ovizio reported a revenue of EUR 1.4 million for their latest financial year, largely from consumables and service contracts.
Who are the main customers of ChemoMetec?
ChemoMetec serves notable pharmaceutical and biotech companies, providing them with advanced measurement instruments.
When was ChemoMetec founded?
ChemoMetec was established in 1997 and is listed on Nasdaq OMX Copenhagen, highlighting its longstanding presence in the market.
